NKARTA INC. - COMMON STOCK

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

09 Nov 2022 15:02:00 By Nasdaq GlobeNewswire

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting

07 Nov 2022 07:52:47 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conferences

02 Nov 2022 07:02:00 By Nasdaq GlobeNewswire

Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights

11 Aug 2022 15:02:00 By Nasdaq GlobeNewswire

Nkarta Announces Key Senior Leadership Team Appointments

25 Jul 2022 15:31:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conference

31 May 2022 06:02:00 By Nasdaq GlobeNewswire

Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

16 May 2022 15:02:00 By Nasdaq GlobeNewswire

Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

12 May 2022 15:02:00 By Nasdaq GlobeNewswire

Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares

28 Apr 2022 15:01:00 By Nasdaq GlobeNewswire

Nkarta Announces Pricing of Upsized Public Offering of Common Stock

25 Apr 2022 22:19:11 By Nasdaq GlobeNewswire

Nkarta Announces Proposed Public Offering of Common Stock

25 Apr 2022 15:01:00 By Nasdaq GlobeNewswire

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

25 Apr 2022 06:00:00 By Nasdaq GlobeNewswire

Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates

22 Apr 2022 15:10:00 By Nasdaq GlobeNewswire

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022

08 Apr 2022 12:25:08 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conference

08 Apr 2022 06:58:00 By Nasdaq GlobeNewswire

Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors

29 Mar 2022 07:02:00 By Nasdaq GlobeNewswire

Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

17 Mar 2022 15:02:00 By Nasdaq GlobeNewswire

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting

08 Mar 2022 15:35:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conferences

10 Feb 2022 07:02:00 By Nasdaq GlobeNewswire

Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML

16 Dec 2021 07:02:00 By Nasdaq GlobeNewswire